Target intelligence / Profile preview

Streptococcus pneumoniae capsular polysaccharides (24 serotypes) (PnPS-24)

Target
PnPS-24
Molecular classification
Polysaccharide, Bacterial antigen
01

Overview

Streptococcus pneumoniae capsular polysaccharides are complex carbohydrate polymers that form the outermost layer of the bacterium, serving as a primary virulence factor by protecting the pathogen from host phagocytosis and complement-mediated killing. There are over 100 known serotypes of S. pneumoniae, distinguished by the unique chemical structure of these polysaccharides, which determine the organism's antigenicity and invasiveness. In the context of a 24-valent vaccine target, these polysaccharides represent a specific set of antigens selected based on their prevalence in causing invasive pneumococcal disease (IPD) and antibiotic resistance. As therapeutic targets, these polysaccharides are utilized in conjugate vaccines where they are chemically linked to carrier proteins to enhance immunogenicity, particularly in infants and the elderly. By introducing these purified polysaccharides into the host, the immune system is primed to produce serotype-specific antibodies that opsonize the bacteria, allowing for efficient recognition and destruction by immune cells. This targeted approach is critical for preventing life-threatening infections such as pneumonia, meningitis, and sepsis. The 24-valent formulation specifically aims to provide broader coverage than existing 13, 15, or 20-valent vaccines by including additional emerging or high-burden serotypes.

Other names
Pneumococcal capsular polysaccharidesS. pneumoniae CPS24-valent pneumococcal polysaccharide antigensPneumococcal surface polysaccharides
02

Mechanism of action

Induction of serotype-specific humoral immunity and opsonophagocytic antibody responses to facilitate bacterial clearance.

03

Biological functions

Bacterial virulence factorImmune evasionAntigenic determinantInhibition of phagocytosis
04

Disease associations

InfectionPneumoniaMeningitisBacteremiaSepsisOtitis media
05

Safety considerations

Serotype replacementInjection site reactionsHypersensitivitySystemic inflammatory response
06

Interacting drugs

VAX-24

2 more in the full profile.

07

Biomarkers

Serotype-specific IgG antibody concentrationOpsonophagocytic activity (OPA) titers

Beyond the preview

Go deeper on Streptococcus pneumoniae capsular polysaccharides (24 serotypes) (PnPS-24).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Streptococcus pneumoniae capsular polysaccharides (24 serotypes) (PnPS-24).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call